Novel anti-viral agents to treat influenza

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$600,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI084244-01A1
Award Id:
95724
Agency Tracking Number:
AI084244
Solicitation Year:
n/a
Solicitation Topic Code:
NIAID
Solicitation Number:
n/a
Small Business Information
ALEXANDER BIODISCOVERIES, LLC, 530 FORREST RD, CHARLOTTESVILLE, VA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
828800040
Principal Investigator:
DIPANWITABASU
(434) 825-5210
ALEXANDERBIODISCOVERIES@GMAIL.COM
Business Contact:
DANIELENGEL
() -
alexanderbiodiscoveries@gmail.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,000 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizations in the United States. In addition, the likelihood of a severe influenza pandemic caused by a newly emergent strain of the virus is very high, given that three such pandemics were recorded in the 20th century. The most devastating of these, the 1918 Spanish Flu, was resp onsible for an estimated 40 million deaths worldwide. The annual vaccine for seasonal influenza is only partially effective in prevention of the disease. Likewise, currently available anti-influenza drugs such as amantadine and oseltamavir are only partial ly effective in treatment and also suffer from problems of viral resistance. Therefore there is an urgent need for additional anti-influenza therapeutics that attack unexploited aspects of viral biology. The proposed research is directed at developing new drugs that can combat influenza virus. The NS1 protein of influenza virus is an attractive drug target because it is essential for virus replication in vivo. Therefore drugs that inhibit NS1 function are expected to block virus replication, and hence disea se. Several compounds that specifically inhibit NS1 function during infection have been identified. These compounds, which represent starting points for further drug development, also inhibit virus replication in cell culture. The goals of this proposal ar e to perform structure-activity and feasibility studies to determine how the first-generation compounds can be chemically modified to increase their potency while at the same time limiting their cellular toxicity. In Aim 1, medicinal chemistry approaches w ill be used to make initial sets of chemical derivatives. The design of these compounds will probe the chemical space around the backbone structures defined by the prototype active compounds. In Specific Aim 2, the derivatives will be tested using a set of biological assays that depend on the function of the NS1 protein. These include virus replication, induction of interferon mRNA, and physical binding to several cellular components including dsRNA and specific cellular proteins. The endpoint of these stud ies will be the identification of potent lead compounds for future development and animal testing. PUBLIC HEALTH RELEVANCE: Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,00 0 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizations in the United States. The proposed research is directed at developing new drugs that can combat the influenza virus, the virus that causes influenza.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government